Ensayos Clínicos Cabeza y Cuello abiertos a reclutamiento (Actualizado abril 2021)

Fuente de información: Clinical trials.gov; EU Clinical Trials Register; REEC (AEMPS)

EudraCT-Nuber	NCT	CÓDIGO-ESTUDIO	TITULO_ESTUDIO	FASE	INDICACÓN	ESTADO	MEDICACIÓN	CENTROS	PROMOTOR
ENSAYOS PROMOVIDOS POR TTCC									
2019-002922-60	4282109	TTCC2019-01/CA209-7HE (NIVOTAX)	Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination With Paclitaxel in Subjects With R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX). **1ºLINEA recurrent/metastatic**	Phase II	**Patients unable for cisplatin-based chemotherapy**	**RECLUTANDO**	**NIVOLUMAB**	ICO_Hospitalet (BCN) H.U.Clinic (BCN) ICO_Badalona (BCN) ICO_Girona (BCN) H.Clinico (Madrid) H 12 Octubre (Madrid) H.U.La Fe (Valencia) H.U.Miguel Servet C.H.Navarra H.C.L.Blesa(Zaragoza) H.U.V.Rocio (Sevilla) H.Regional (Malaga) H.Clinico Valencia H.U.V.Nieves (Granada) H.U.V.Salud (Toledo) C.H.Salamanca C.O.Galicia(Coruña) H.U.Donosti(S.Sebastian) H.U.M.Valdecilla. H.U.Lucus Augusti(Lugo)	**TTCC**
N.A	4672772	**TTCC-2019-02 (ERBITAX)**	Retrospective Study With Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN (Squamous Cell Carcinoma of the Head and Neck): **Real World Data**	RETROSPECTIVE	The main objective will be to estimate the Progression-free survival (PFS) in patients treated with paclitaxel 80 mg/m2 as a starting dose, with weekly cetuximab that could have been switched to biweekly during the maintenance phase, as first line for recurrent and/or metastatic SCCHN.	**RECLUTANDO**	**Cetuximab Paclitaxel**	ICO_Hospitalet (BCN) ICO_Badalona (BCN) ICO_Girona (BCN) H.Clinico (Madrid) H 12 Octubre (Madrid) H.U.M. Servet(Zaragoza) C.H.Navarra (Pamplona) H.U.V.Valme (Sevilla) H.R.Universitario (Malaga) H.U.Lucus Augusti (Lugo) H.U.V.Nieves (Granada) C.H.Salamanca C.O.Galica(Coruña) H.M.Valdecilla(Santander) H.U.Son Espases (P.M) H.U.Tenerife (Canarias)	**TTCC**
OTROS PROMOTORES									
2017-001139-38	3765918	**MK3475-689**	Estudio de fase III, aleatorizado y abierto para evaluar pembrolizumab como **tratamiento neoadyuvante** y en combinación con la asistencia habitual como tratamiento adyuvante en el carcinoma epidermoide de cabeza y cuello locorregionalmente avanzado **(CECC LA)**, extirpable, en estadio III-IVA.	Phase III	carcinoma epidermoide de cabeza y cuello locorregionalmente avanzado (CECC LA), extirpable , en estadio III-IVA	**RECLUTANDO**	Pembrolizumab Cisplatin	H.U.de Santiago H.U.La Paz (Madrid) H.U.V.Rocio (Sevilla) ICO-Hospitalet (BCN) ICO-Badalona (BCN) H.U.Vall d´Hebron (BCN)	Merck-Sharp & Dohme Corp.
2019-003717-34	4199104	**MK-7902-010**	A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as **1L Intervention** in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma **(R/M HNSCC)** (LEAP-010).	Phase III	This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma.**ECOG:0-1**	**RECLUTANDO**	Pembrolizumab Lenvatinib	ICO_Hospitalet (BCN) H.U.Vall d´Hebron (BCN) H.U 12 Octubre (Madrid) H.U.La Paz (Madrid) H.U.L. Blesa (Zaragoza) H.U.V.de Valme (Sevilla)	Merck Sharp & Dohme Corp.
2019-003981-42	**4428333**	**209227**	A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase III	This will be a randomized, parallel group treatment study with eligible participants receiving either GSK3359609 in combination with pembrolizumab and 5FU-platinum chemotherapy or placebo in combination with pembrolizumab and 5FU-platinum chemotherapy.	**RECLUTANDO**	Drug: feladilimab Drug: Pembrolizumab Drug: Placebo Drug: Platinum based chemotherapy Drug: Fluorouracil (5FU)	H.U.Vall d´Hebron (BCN) H.U 12 Octubre (Madrid) H.U.La Paz (Madrid) H.Clinico (Madrid) CIOCC_(Madrid) H.U.La FE (Valencia) H.U.V.Macarena(Sevilla)	GlaxoSmithKline
2018-001437-40	3719690	**KO-TIP-007**	El estudio AIM-HN y SEQ-HN: Estudio pivotal no comparativo de 2 cohortes para evaluar la eficacia de tipifarnib en pacientes con **carcinoma de células escamosas de cabeza y cuello (CCECC) con mutaciones de HRAS** (AIM-HN) y el impacto de las mutaciones de HRAS en la respuesta a las terapias sistémicas de primera línea para el CCECC (SEQ-HN).	Phase II	Carcinoma de células escamosas de cabeza y cuello **(CCECC) recurrente o metastásico con mutaciones en HRAS**	**RECLUTANDO**	Tipifarnib (oral)	H.Vall d´Hebron (BCN) H.U.Clinic (BCN) H.U. Sant Pau (BCN) ICO_Hospitalet (BCN) H.del Mar (BCN) H La Paz (Madrid) H 12 Octubre (Madrid) H.U.Sanchinarro(Madrid) H.U.La Fe (Valencia) H.U.M.Servet (Zaragoza) C.H.Navarra (Pamplona) H.U.Santiago de Compostela H.U.V.Rocio (Sevilla) H.U.V.Victoria (Malaga) H.Costa del Sol (Malaga)	Kura_Oncology, Inc
2019-002263-99	4128696	**209229**	A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for **First-Line Treatment of PD-L1 Positive** Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase II/III	Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)	**RECLUTANDO**	GSK3359609 & Pembrolizumab & Placebo	H.U.Clinic(BCN) H.U.Vall d´Hebron (BCN) ICO_Hospitalet (BCN) H.U.V.Victoria(Malaga) H.U.G.Marañon(Madrid) H.U.Ramon y Cajal (Madrid) H.U.La Paz (Madrid) H.U.Quiron (Madrid) H.U.M. Servet (Zaragoza) H.U.Santiago de Compostela	GlaxoSmithKline & Merck Sharp & Dohme Corp.
2019-000569-19	4428151	**MK-7902-009**	A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009) **2ªLinea añade Lenva a PD a Inmunoterapia.**	Phase II	Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) which has progressed after treatment with both platinum therapy and most recently immunotherapy	**RECLUTANDO**	Pembrolizumab & Lenvatinib	ICO-Hospitalet (BCN) H.General Valencia H.U.Vall d´Hebron(BCN) H.U.Ramon y Cajal (Madrid) H.U.V. Victoria (Málaga)	Merck Sharp & Dohme Corp. Eisai

2018-002513-36	3769506	**ASP-1929-301**	A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician´s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or **After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy**	Phase III	Locoregional, recurrent head and neck squamous cell carcinoma	**RECLUTANDO**	ASP-1929 Photoimmunotherapy	H.U.Sanchinarro (Madrid) H.U.Vall d´Hebron (BCN)	Rakuten Aspyrian, Inc
2019-004770-25	4590963	**D7310C00001**	A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the **Head and Neck Previously Treated With an Immune Checkpoint Inhibitor**	Phase III	This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in patients with recurrent or metastatic head and neck cancer.	**RECLUTANDO**	Monalizumab Cetuximab	4 Sites Madrid 1 Site Barcelona 1 Site Valencia 1 Site Zaragoza	AstraZeneca
2018-000789-13	3669718	**ISA101B-HN-01-17**	Estudio de fase II, aleatorizado, con doble enmascaramiento y controlado con placebo de cemiplimab en comparación con la combinación de cemiplimab más ISA101b en el tratamiento de sujetos con **cáncer orofaríngeo (COF) VPH16 -positivo resistente al platino**	Phase II	**Cáncer orofaríngeo** (COF) VPH-16 positivo resistente al platino	**RECLUTANDO**	Human Papilloma Virus (HPV) type 16 E6/E7 synthetic long peptide (SLP®) vaccine	ICO-Hospitalet (BCN) H.U.12-Octubre (Madrid) H.C.San Carlos (Madrid) H.U.SanChinarro(Madrid) H.U.La Paz (Madrid) H.U.Clinic (BCN) H.U.Vall d´Hebron(BCN) H.U.Salamanca H.U.V.Victoria(Malaga) H.U.M. Valdecilla (Santander)	ISA-Therapeutics B.V
2018-001095-38	3799744	**ICO-VCN-H&N_2018**	A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the **Head and Neck**	Phase I	Metastasis & Recurrence	**RECLUTANDO**	Genitic:VCN-01 Biological: Durvalumab	ICO_Hospitalet (BCN) H.U.Vall d´Hebron(BCN)	**ICO** ***Collaborators:*** VCN Biosciencces S.L BioClever 2005 S.L Astra Zeneca
2019-003167-22	4196283	**M19-894**	A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With **Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma**	Phase I	The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).	**RECLUTANDO**	ABBV-368 Tilsotolimod D Nab-paclitaxel ABBV-181	H.Clinic (BCN) ICO-Hospitalet (BCN) H.U.12 Octubre (Madrid) Start_Sanchinarro(Madrid) H.U.V.Victoria (Málaga) H.Clinico (Valencia) H.U.Fuenlabrada (Madrid)	AbbVie / Idera Pharmaceuticals, Inc

Tumores Sólidos con Cohorte de Cancer de Cabeza y Cuello

2018-001608-12	**3645928**	**IOV-COM-202**	Estudio Fase II, multicentrico de linfocitos de tumores autologos (LN-144 ó LN-145)en pacientes con **SOLID TUMORS.**	Phase II	Tumores sólidos incluyendo melanoma metastásico avanzado (MM) o irresecable, **carcinoma epidermoide de cabeza y cuello avanzado (CECC)** y cáncer de pulmón no microcítico (CPNM) . **1ªLINEA o SUCESIVAS**	**RECLUTANDO**	Proleukin Pembrolizumab	H.U.Vall d´Hebron (BCN) ICO-Duran i Reynals (BCN) H.U.12 Octubre (Madrid) H.U.SanChinarro (Madrid) H.U.G.Marañon (Madrid) F.J.Diaz(Madrid) H.R.U.Málaga H.U.Valdecilla (Santander)	Iovance Biotherapeutics.Inc
2017-005076-26	3485209	**SGNTV-001**	Open label phase 2 study of Tisotumab Vedotin for locally advanced or metastatic disease in **SOLID TUMORS.**	Phase II	4 _COHORTS: Colorectal , NSCLC, Exocrino pancreatic adenocarcinoma and **SCCHN**	**RECLUTANDO**	Tisotumab vedotin	H.Vall d´Hebron (BCN) H.U.Ramon y Cajal (Madrid) H.U.Sanchinarro (Madrid) H.Quironsalud (BCN) ICO_Badalona (BCN)	Seattle Genetics, Inc
2017-000241-49	3207867	**CNIR178X2201**	A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With **Selected Advanced Solid Tumors** and Non-Hodgkin Lymphoma	Phase II	NSCLC, Non Small Cell Lung Cancer RCC, Renal Cell Cancer Pancreatic Cancer Urothelial Cancer **Head and Neck Cancer** DLBCL, Diffused Large B Cell Lymphoma MSS, Microsatellite Stable Colon Cancer TNBC, Triple Negative Breast Cancer Melanoma	**RECLUTANDO**	NIR178 & PDR001	H.U.Vall d´Hebron(BCN)	Novartis Pharmaceuticals
2015-003385-84	2568267	**GO40782 (RXDX-101-02)**	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic **Solid Tumors** That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Phase II	Breast Cancer, Cholangiocarcinoma Colorectal Cancer, **Head and Neck** Neoplasms Lymphoma, Large-Cell, AnaplasticMelanoma ,Neuroendocrine, Tumors Non-Small Cell Lung, CancerOvarian Cancer Pancreatic, **CancerPapillary Thyroid,** CancerPrimary Brain TumorsRenal Cell Carcinoma Sarcomas,**Salivary Gland** Cancers Adult Solid Tumor	**RECLUTANDO**	ENTRECTINIB	H.U.Vall d´Hebron (BCN) H.U.12 Octubre (Madrid) H.U.Ramon y Cajal (Madrid) START Sanchinarro (Madrid) H.U.V.Victoria (Malaga) H.C.U.San Carlos (Madrid) H.U.Virgen Rocio (Sevilla)	Hoffmann-La Roche/ **Ignyta**, Inc
2018-001994-25	3625323	**TACTI-002(PO15 KEYNOTE-PN798**	TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or with **recurrent or metastatic squamous head and neck cancer (HNSCC)** receiving the soluble LAG-3 fusion protein eftilagimod alpha (IMP321) in combination with pembrolizumab (PD-1 antagonist)	Phase II	Recurrent or metastatic squamous head and neck cancer (HNSCC)	**RECLUTANDO**	IMP321 Pembrolizumab	H.Santa Creu i Sant Pau ICO-Badalona (BCN) H.U.Vall d´Hebron(BCN) F.J.Diaz (Madrid)	IMMUTEP S.A.S
2015-003582-28	2576431	**LOXOTRX-15002 (NAVIGATE)**	A **Phase 2 Basket Study** of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors	Phase II	The primary objective of this study is to investigate the efficacy of larotrectinib for the treatment of advanced solid tumors harboring a fusion of neurotrophic tyrosine receptor kinase (NTRK) of types 1-3 in **children and adults. ARM8 H&N:** Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles,	**RECLUTANDO**	Larotrectinib (LOXO-101)	H.U.Vall d´Hebron(BCN) H.U.Sanchinarro(Madrid) F.Jimenez Diaz (Madrid) H.U. Valdecilla(Santander) H.General de Valencia	Bayer
2018-003402-63	3917381	**GCT1046-01**	First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With **Malignant Solid Tumors**	**Ph1, first-in-human (FIH) and an expansion part (phase 2a)**	The trial is an open-label, multi-center safety trial of GEN1046. The trial consists of two parts, a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase 2a)). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined	**RECLUTANDO**	GEN1046	Clinica.U.de Navarra H.U.Vall d´Hebron (BCN) START-FJD(Madrid) START_Sanchinarro(Madrid) H.Clinico de Valencia H.U.12 Octubre (Madrid)	Genmab A/S
2018-003555-38	3729596	**IP-MGC018-01**	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors	**Phase 1/2, First-in-Human**	The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of MGC018 administered alone and in combination with MGA012 in patients with advanced solid tumors	**RECLUTANDO**	MGC018 MGA012	H.Ruber Internacional(Madrid)	MacroGenics

2019-003998-26	4424641	**GCT1044-01**	First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With **Malignant Solid Tumors**	First in human	The trial is an open-label, multi-center safety trial of GEN1044. The trial consists of two parts: a dose escalation part (phase 1) and an expansion part (phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined from phas	**RECLUTANDO**	Biological: GEN1044 (is an IgG1 bispecific antibody targeting CD3 and 5T4).	H.Vall d´Hebron (BCN) START_F. J.Diaz (Madrid)	Genmab/AbbVie
2016-002219-16	2988960	**M15-862**	A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With **Advanced Solid Tumor**	Phase I	Advanced, solid tumors, squamous cell cancer of the **head and neck**, pancreatic cancer, non-small cell lung cancer, melanoma	**RECLUTANDO**	ABBV-927 & ABBV-181	START_Sanchinarro(Madrid) H.U.P. de Hierro (Madrid) H.U.La Fé (Valencia) START_F. J.Diaz (Madrid)	AbbVie
2019-000446-36	3894618	**SL01-DEL-101**	Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With **Advanced Solid Tumors** or Lymphomas	Phase I	**Squamous Cell Carcinoma of the Head and Neck**, MelanomaNon Small Cell Lung CancerUrothelial CarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the SkinRenal Cell CarcinomaHodgkin LymphomaDiffuse Large B Cell LymphomaMismatch Repair Deficient or MSI-High Solid Tumors	**RECLUTANDO**	SL-279252	H.U.Vall d´Hebron (Barcelona)	Shattuck Labs, Inc.
UK	1351103	**CLGK974X2101**	A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands	Phase I	This primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected **solid malignancies** for whom no effective standard treatment is available.	**RECLUTANDO**	Drug:LGK974 Biological: PDR001	2 Sites Barcelona 2 Sites Madrid	Novartis Pharmaceuticals
2018-004334-15	**4234113**	**SC103**	A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in **Patients With Selected Advanced/Metastatic Solid Tumors**	Phase I	**HNSCC & Thyroid**, A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors	**RECLUTANDO**	SO-C101 Pembrolizumab	H.U.Vall d´Hebron(BCN)	SOTIO
2016-003429-41	3291002	**CV-8102-008**	Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, **Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinom**	Phase I	This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.	**RECLUTANDO**	Biological: CV8102 Biological: CV8102 + anti-PD-1 therapy	H.U.Vall d´Hebron (BCN) H.U.V.Victoria (Málaga)	CureVac AG / Syneos Health
2019-004748-31	4254107	**SGNTGT-001**	A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With **Advanced Malignancies**	Phase I	Part C will study how well SEA-TGT with pembrolizumab works to treat solid tumors. Pembrolizumab is a drug that can be used to treat these types of cancer.	**RECLUTANDO**	SEA-TGT Pembrolizumab	H.Vall d´Hebron (BCN)	Seagen Inc.
2017-001475-23	**3289962**	**GO39733**	A phase 1a/1b, open-label, dose escalation study of the safety and PKs of RO7198457 as a single agent and in combination with Atezolizumab in patients with **locally advanced or metastatic Tumors.**	Phase Ia/Ib	8_COHORTS: Melanoma, Bladder Ca, NSCLC, Colorectal, Triple Negative Breast Ca, Renal Ca, **H&N Cancer** , other Solid Cancers.	**RECLUTANDO**	Atezolizumab RO7198457	H.U.Vall d´Hebron (BCN) C.U.Navarra(Pamplona)	Genentech,Inc
2017-001553-14	3150810	**BGB-290-103**	A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic **Solid Tumors**	Phase Ib	he primary objective of this study is to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the antitumor activity of pamiparib in combination with TMZ.	**RECLUTANDO**	Pamiparib Temozolomide	H.Vall d´Hebron (BCN) ICO-Hospitalet (BCN) Start_F.J. Diaz (Madrid) Start_Sanchinarro (Madrid) H.Clinico (Valencia)	BeiGene
2018-001456-34	3543813	**CTMX-M-2029-001**	A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable **Solid Tumors** or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)	Phase I/II	The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL). PROCLAIM: PRObody CLinical Assessment In Man CX-2029 clinical trial 001	**RECLUTANDO**	CX-2029	H.Clinic (BCN) H.U.La Paz (Madrid) Start_Sanchinarro (Madrid) H.Valle'Hebron (BCN) H.Quiron(Madrid)	CytomX Therapeutics
2018-004771-12	4000529	**CTNO155B12101**	A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib **in Selected Malignancies**	Phase Ib	This study is a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors.	**RECLUTANDO**	TNO155 Spartalizumab Ribociclib	H.Vall d´Hebron (BCN)	Novartis Pharmaceuticals
2016-001860-12	**2900651**	**CMAK683X2101**	A phase I/II, multicenter, open-label study of MAK683 in adult patients with **advanced malignancies**	Phase I/II	H&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.	**RECLUTANDO**	MAK683	H.U.12 Octubre (Madrid)	Novartis Pharmaceuticals
2017-001792-24	3170960	**XL184-021**	A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase Ib	H&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy	**RECLUTANDO**	Atezolizumab Cabozantinib	24 Sites in Spain	Exelixis
UK	3212404	**CK-301-101**	A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers	Phase I	CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.	**RECLUTANDO**	CK-301 (cosibelimab)	Barcelona Madrid Málaga Pamplona La Laguna (Tenerife) Valencia Sevilla	Checkpoint Therapeutics, Inc. Novotech (Australia) Pty Limited

2017-001475-23	3289962	GO39733	A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumor	Phase Ia/Ib	This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).	RECLUTANDO	Autogene cevumeran & Atezolizumab	H.Vall d'Hebron(BCN) C.U.Navarra (Pamplona)	Genentech, Inc.
2019-000478-45	3893955	M19-037	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic **Solid Tumors**	Phase I	Advanced Solid, TumorsTriple-Negative Breast Cancer (TNBC),Non-small-cell-lung-cancer (NSCLC),**Head and Neck Squamous Cell Carcinoma** (HNSCC), Metastatic Solid Tumors	RECLUTANDO	ABBV-927 ABBV-368 ABBV-181 Docetaxel	H.Vall d´Hebron (BCN) H.V.Victoria (Málaga) START_F.J.Diaz (Madrid) START_Sanchinarro(Madrid)	AbbVie
2019-004539-22	4504669	D9950C00001	A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced **Solid Tumours.**	Phase I	The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors	RECLUTANDO	AZD8701	1 Site Barcelona 1 Site Pamplona	AstraZeneca
2019-003474-35	3138889	16-214-05	A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic **Solid Tumors**	Phase I/II	This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®).	RECLUTANDO	NKTR-214 Pembrolizumab	3 Sites Madrid 2 Sites Barcelona 1 Site La Laguna(Tenerife)	Nektar Therapeutics
2019-003825-56	4261179	SENTINELSEEK-HC	An Exploratory Prospective, Open-label, Unicentric Study With Cross-over Design, Comparing Lymphoseek® vs. Albumin Nanocolloid for Image- Guided Sentinel Lymph Node Mapping **in Head and Neck**, Melanoma and Breast Cancer.(SENTINELSEEK)	Phase IV	Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams	Not yet recruiting (30/04/21)	Lymphoseek Nanocoll	H.U.Clinic (BCN)	Fundacion Clinic per a la Recerca Biomédica
UK	4721184	PR299/20	Prospective: Impact of Body Composition on the Prognosis and Toxicity of Patients Diagnosed With Recurrence or Metastasic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treated With Immune Checkpoint Inhibitors (ICI)	Prospectivo	The purpose of the study is to evaluate the baseline muscle mass as a predictive biomarker of treatment response in patients with recurrence or metastatic squamous cell carcinoma of the head and the neck (SCCHN) treated with immune checkpoint inhibitors (ICI)	RECLUTANDO	N.A	L'Hospitalet De Llobregat (BCN)	Institut Català d'Oncologia Department of Health, Generalitat de Catalunya
UK	4145180	0045-N-16	Effectiveness of a Physical Recovery Program for **Head and Neck Cancer Patient**s (3C-CUIDATE)	Prospectivo	This project intends to carry out an experimental randomized controlled study with 84 patients treated of head and neck cancer who will be assigned randomly to the study groups: a) manual therapy program or, b) control group. The assessment refers to a baseline form (at the beginning of the study), at 6 weeks and at 6 months of patient follow-up.	RECLUTANDO	Manual therapy	Universidad de Granada	Universidad de Granada
UK	4110977	RAREST-02	RAdiotherapy RElated Skin Toxicity: A Reminder App to Reduce Radiation Dermatitis Rates in Patients With **Head-and-Neck Cancer**	UK	The goal of this trial is to investigate whether the addition of a reminder app to standard care leads to a reduction of dermatitis and oral mucositis during radio(chemo)therapy for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).	RECLUTANDO	Mobile application (reminder app)	H.U.de Cruces (Bilbao) H.U.La Fe(Valencia)	University Hospital Schleswig-Holstein
2018-003352-20	3768063	BO40729	An Open Label, Multicenter Extension Study in **Patients Previously Enrolled in a Genentech** and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)	Phase IV	**Squamous cell carcinoma of head and neck**, Solid Tumors, NSCLC, Urothelial carcinoma, Renal cell carcinoma	RECLUTANDO	Atezolizumab	C.U.Navarra H.U.Sanchinarro (Madrid) H.Sabadell (BCN)	Hoffmann-La Roche

ESPECIALIDAD
Oncologia_medica
Oncologia_medica
Oncologia_medica N=704
Oncologia_medica N=500
Oncologia_Medica
Oncologia_medica
Oncologia_medica
Oncologia_medica

Oncologia_medica

Oncologia_medica

Oncologia_medica

Oncologia_medica
N= 20

Oncologia_medica

Oncologia_medica

Oncologia_medica

Oncologia_medica

Oncologia_medica

Oncologia_medica

Onclologia Medica
N= 203
12 years and older

Oncologia_medica

Oncologia_medica

Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica

Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncologia_medica
Oncología
Oncología
Oncologia_radioterápica
Oncologia_medica